Edition:
India

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

7,152JPY
20 Sep 2019
Change (% chg)

¥26 (+0.36%)
Prev Close
¥7,126
Open
¥7,111
Day's High
¥7,224
Day's Low
¥7,074
Volume
1,909,000
Avg. Vol
1,809,847
52-wk High
¥7,358
52-wk Low
¥3,277

Select another date:

Sat, Aug 3 2019

U.S. FDA approves Daiichi Sankyo's treatment for rare joint tumor

The U.S. Food and Drug Administration on Friday approved Daiichi Sankyo Co Ltd's treatment for adult patients with a type of rare, non-cancerous tumor affecting joints and limbs.

UPDATE 1-U.S. FDA approves Daiichi Sankyo's treatment for rare joint tumor

Aug 2 The U.S. Food and Drug Administration on Friday approved Daiichi Sankyo Co Ltd's treatment for adult patients with a type of rare, non-cancerous tumor affecting joints and limbs.

U.S. FDA approves Daiichi Sankyo's treatment for rare joint tumor

Aug 2 The U.S. Food and Drug Administration (FDA) on Friday approved Daiichi Sankyo Co Ltd's treatment for adult patients with a type of rare, non-cancerous tumor usually affecting joints and limbs.

FDA declines to approve Daiichi Sankyo's blood cancer treatment

Japan's Daiichi Sankyo Co said on Friday the U.S. Food and Drug Administration has declined to approve its drug quizartinib as a treatment for adults with a type of blood cancer.

FDA declines to approve Daiichi Sankyo's blood cancer treatment

Japan's Daiichi Sankyo Co said on Friday the U.S. Food and Drug Administration has declined to approve its drug quizartinib as a treatment for adults with a type of blood cancer.

UPDATE 1-FDA declines to approve Daiichi Sankyo's blood cancer treatment

June 21 Japan's Daiichi Sankyo Co said on Friday the U.S. Food and Drug Administration has declined to approve its drug quizartinib as a treatment for adults with a type of blood cancer.

FDA declines to approve Daiichi Sankyo's blood cancer treatment

June 21 Japan's Daiichi Sankyo Co said on Friday the U.S. Food and Drug Administration has declined to approve its drug quizartinib as a treatment for adults with a type of blood cancer.

Daiichi Sankyo looking to sell OTC drug unit for about $900 million: Nikkei Business

TOKYO Japan's Daiichi Sankyo Co Ltd is in talks with several companies to sell its wholly owned over-the-counter (OTC) drug unit, with the final price likely to reach around 100 billion yen ($900 million), Nikkei Business reported on Thursday.

UPDATE 2-Daiichi Sankyo looking to sell OTC drug unit for about $900 mln -Nikkei Business

* Company denies it is negotiating sale of unit (Adds company comment, background)

Daiichi Sankyo looking to sell OTC drug unit for about $900 mln - Nikkei Business

TOKYO, May 23 Japan's Daiichi Sankyo Co is in talks with several companies to sell its wholly owned over-the-counter drug unit, with the final price likely to reach around 100 billion yen ($900 million), Nikkei Business reported on Thursday.

Select another date: